![Scott Reents](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Scott Reents
Finansdirektör/CFO på TOBIRA THERAPEUTICS INC
Förmögenhet: 2 M $ per 30.06.2025
Profil
Scott T.
Reents currently works at Allergan, Inc., as President & Director, Oculeve, Inc., as President & Director, Cerevel Therapeutics Holdings, Inc., as President & Director from 2024, Allergan GI Corp., as President & Director, AbbVie, Inc., as Chief Financial Officer & Executive Vice President from 2022, Tobira Therapeutics, Inc., as Chief Financial Officer, and Landos Biopharma, Inc., as President.
Mr. Reents also formerly worked at Abbott Laboratories, as Vice President-Tax.
Mr. Reents received his undergraduate degree from the University of Nebraska and graduate degree and Masters Business Admin degree from the University of Washington.
Kända innehav i offentliga företag
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
ABBVIE, INC. 0 % | 14.03.2025 | 11 577 ( 0 % ) | 2 M $ | 30.06.2025 |
Senaste nyheterna om Scott Reents
Aktiva positioner av Scott Reents
| Företag | Position | Start |
|---|---|---|
| TOBIRA THERAPEUTICS INC | Finansdirektör/CFO | - |
| ABBVIE INC. | Finansdirektör/CFO | 23.06.2022 |
| ALLERGAN, INC. | President | - |
| CEREVEL THERAPEUTICS HOLDINGS, INC. | President | 01.08.2024 |
| LANDOS BIOPHARMA, INC. | President | - |
Oculeve, Inc.
 Oculeve, Inc. Medical SpecialtiesHealth Technology Oculeve, Inc. develops devices for dry eye disease treatment. The company was founded by D. Michael Ackermann, Brandon M. Felkins, Garrett Cale Smith and Victor Wayne McCray in 2011 and is headquartered in Parsippany, NJ. | President | - |
Allergan GI Corp.
 Allergan GI Corp. BiotechnologyHealth Technology Allergan GI Corp. develops peptide therapeutics for the treatment of gastrointestinal disorders. It provides RM-493 a small-peptide melanocortin-4 receptor agonist, for the treatment of obesity and diabetes, and RM-131 a small-peptide ghrelin agonist, for the treatment of diabetic gastro paresis and other gastrointestinal functional disorders. The company was founded by Bart Henderson and Elizabeth Stoner in 2008 and is headquartered in Madison, NJ. | President | - |
Tidigare kända positioner av Scott Reents
| Företag | Position | Slut |
|---|---|---|
| ABBOTT LABORATORIES | Comptroller/Controller/Revisor | - |
Utbildning av Scott Reents
University of Nebraska | Undergraduate Degree |
University of Washington | Graduate Degree |
Erfarenheter
Innehade positioner
Relationer
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Börsnoterade företag | 2 |
|---|---|
| ABBVIE INC. | Health Technology |
| ABBOTT LABORATORIES | Health Technology |
| Privata företag | 6 |
|---|---|
Tobira Therapeutics, Inc.
 Tobira Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company was founded on September 11, 2006 and is headquartered in Madison, NJ. | Health Technology |
Allergan, Inc.
 Allergan, Inc. Pharmaceuticals: MajorHealth Technology Allergan, Inc. operated as a global healthcare company. It engaged in the development and commercialization of specialty pharmaceutical, medical device ,and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological, and other specialty markets. The company was founded by Gavin S. Herbert Sr. in 1950 and headquartered in Irvine, CA. | Health Technology |
Oculeve, Inc.
Oculeve, Inc. Medical SpecialtiesHealth Technology Oculeve, Inc. develops devices for dry eye disease treatment. The company was founded by D. Michael Ackermann, Brandon M. Felkins, Garrett Cale Smith and Victor Wayne McCray in 2011 and is headquartered in Parsippany, NJ. | Health Technology |
Cerevel Therapeutics Holdings, Inc.
 Cerevel Therapeutics Holdings, Inc. Pharmaceuticals: MajorHealth Technology Cerevel Therapeutics Holdings, Inc. engages in the discovery and development of new therapies for neuroscience diseases. The firm's portfolio focuses on diseases such as schizophrenia, epilepsy, and Parkinson's disease. Its product candidates include CVL-231, Darigabat, Tavapadon, CVL-871, and CVL-936. The company was founded in 2018 and is headquartered in Cambridge, MA. | Health Technology |
Allergan GI Corp.
Allergan GI Corp. BiotechnologyHealth Technology Allergan GI Corp. develops peptide therapeutics for the treatment of gastrointestinal disorders. It provides RM-493 a small-peptide melanocortin-4 receptor agonist, for the treatment of obesity and diabetes, and RM-131 a small-peptide ghrelin agonist, for the treatment of diabetic gastro paresis and other gastrointestinal functional disorders. The company was founded by Bart Henderson and Elizabeth Stoner in 2008 and is headquartered in Madison, NJ. | Health Technology |
Landos Biopharma, Inc.
 Landos Biopharma, Inc. BiotechnologyHealth Technology Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of novel, oral, once-daily therapeutics for patients with certain immunology diseases. It offers NX-13, a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway. The firm's preclinical candidates include LABP-73, LABP-66, and LABP-69. The company was founded by Josep Bassaganya-Riera in January 2017 and is headquartered in Blacksburg, VA. | Health Technology |
